Clinical Trials Logo
  1. Home
  2. Bacterial Vaginoses
  3. NCT03954990

Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity

Bacterial Vaginoses Clinical Trial

Official title:
Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity: A Randomized Controlled Trial

Clinical Trial Summary

Bacterial vaginosis (BV) is the most common cause of vaginal discharge among repro-ductive aged women. It is been linked to adverse maternal and neonatal outcomes. Our objective is to evaluate if the use of a single dose of metronidazole in women with BV at time of delivery reduces infectious morbidities

Clinical Trial Description

The investigators are proposing a double-blinded, placebo controlled, randomized trial of 525 pregnant women undergoing induction or admitted in early labor and who are diagnosed with bacterial vaginosis. On admission to labor and delivery, patient will be counseled about the study. Patients who agree to be enrolled, will sign informed consent. Following enrollment patients will be screened for Bacterial vaginosis by doing a speculum exam and testing for Amsel's criteria. BV +ve patients will be randomized to receive either metronidazole 2 grams PO once or identically appearing placebo. The PI, study coordinator, or a collaborator will be responsible for the informed consent. This will be a double-blinded randomized clinical trial. Neither the patient nor provider will be aware of treatment assignment. As with any other in-stance in which antibiotics are administered, there is a chance of an allergic or other adverse reaction. The patient will receive standard inpatient monitoring during the labor course and in the postpartum period, and so any immediate adverse reaction would be promptly detected. Patient will be assessed intrapartum for development of chorioamninoitis. Postpartum patient will be assessed for infective complications up to 4 weeks. Neonates will be assessed for morbidities by chart review for 90 days. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03954990
Study type Interventional
Source The University of Texas Medical Branch, Galveston
Contact
Status Terminated
Phase Phase 1
Start date October 11, 2019
Completion date September 26, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04329338 - Effects of Lactobacillus Pentosus KCA1 on the Gut and Vaginal Microbiome of Women With Bacterial Vaginosis N/A
Completed NCT03837015 - Estrogen, Probiotics and Vaginal Health to Prevent HIV Infection in ACB Women Phase 1
Completed NCT03937869 - Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV Phase 4
Completed NCT03878511 - Therapeutic Lactose to Support Vaginal Microbiota N/A
Not yet recruiting NCT04846361 - Vaginal Hygiene Wash as Adjunct Treatment in Bacterial Vaginosis N/A
Completed NCT04057482 - Treatment of BV With Donaxyl and a Molecular Test of Cure
Completed NCT04393857 - The Temporo-spatial Dynamics of Genital Tract Microbiota - an Observational Study in Oocyte Donors
Completed NCT04414527 - Effects of Video-based Health Education on Maternal and Child Health in Ethiopia N/A
Recruiting NCT04807842 - Multi-Gyn ActiGel Plus for Treatment of Bacterial Vaginosis N/A
Recruiting NCT05166746 - The Effect of Clindamycin and a Live Biotherapeutic on the Reproductive Outcomes of IVF Patients With Abnormal Vaginal Microbiota Phase 2
Completed NCT04189744 - The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract Phase 3
Recruiting NCT04517487 - Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis N/A
Recruiting NCT04885556 - Evaluation of a Novel Female Hygiene Device for Postcoital Discomfort N/A
Terminated NCT04578015 - A Randomized Controlled Trial of Treatment of Bacterial Vaginosis Phase 4
Completed NCT06104098 - A User Study With Vernivia® for Bacterial Vaginosis. N/A